"...the company is too focussed on US market" Maybe. But the US...

"...the company is too focussed on US market"

Maybe. But the US is the biggest market. It would be great if GID can improve algorithms to address FDA concerns about incidence of hepatic abscess. GID seems confident.

Last month GID President/CEO Scott Schorer unveiled a seven point plan for 2017. He says GID will:

1. Support commercialization, market access and reimbursement efforts underway in the UK, Germany, the Middle East and select European countries;

2. Build relationships with regulatory agencies in Europe and the US as the company finalizes the protocol for its pivotal US IDE/investigational device exemption trial;

3. Initiate and begin to enroll the trial this year;

4. Raise capital for executing US clinical development and commercial plans;

5. Establish a Scientific Advisory Board comprising leading experts in treatment/management options for patients with type 2 diabetes and obesity;

6. Bolster efficacy and safety profile for EndoBarrier with presentations/publications based on data generated from multiple post-marketing and investigator-initiated studies;

7. Evolve and add to its team.

All of this should generate news flow.

Meanwhile, $GID today surged to another 52 week high on higher turnover. At close of trade the shares bid/offer ratio was 8:1.